Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.43
HSP's Cash to Debt is ranked higher than
50% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. HSP: 0.43 )
HSP' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.43

Equity to Asset 0.48
HSP's Equity to Asset is ranked higher than
54% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. HSP: 0.48 )
HSP' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.69
Current: 0.48

0.34
0.69
Interest Coverage 0.19
HSP's Interest Coverage is ranked lower than
60% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.51 vs. HSP: 0.19 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 0.19

0.19
9999.99
F-Score: 3
Z-Score: 2.61
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.41
HSP's Operating margin (%) is ranked higher than
55% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. HSP: 0.41 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 0.41

0.41
16.17
Net-margin (%) -0.21
HSP's Net-margin (%) is ranked higher than
54% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. HSP: -0.21 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: -0.21

-0.23
11.4
ROE (%) -0.28
HSP's ROE (%) is ranked higher than
54% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. HSP: -0.28 )
HSP' s 10-Year ROE (%) Range
Min: -0.32   Max: 30.65
Current: -0.28

-0.32
30.65
ROA (%) -0.13
HSP's ROA (%) is ranked higher than
56% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. HSP: -0.13 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 12.87
Current: -0.13

-0.16
12.87
ROC (Joel Greenblatt) (%) 0.65
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. HSP: 0.65 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.65   Max: 30.37
Current: 0.65

0.65
30.37
Revenue Growth (%) 1.50
HSP's Revenue Growth (%) is ranked higher than
62% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HSP: 1.50 )
HSP' s 10-Year Revenue Growth (%) Range
Min: -0.9   Max: 12.4
Current: 1.5

-0.9
12.4
EBITDA Growth (%) -32.30
HSP's EBITDA Growth (%) is ranked lower than
53% of the 504 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.00 vs. HSP: -32.30 )
HSP' s 10-Year EBITDA Growth (%) Range
Min: -32.3   Max: 15.4
Current: -32.3

-32.3
15.4
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

HSP Guru Trades in Q2 2013

Steven Cohen 5,983 sh (New)
Brian Rogers 2,750,000 sh (+135.3%)
John Rogers 4,811,105 sh (+12.97%)
Larry Robbins 4,202,931 sh (+11.68%)
Meridian Funds 257,400 sh (+8.42%)
Jeff Auxier 278,504 sh (+4.27%)
Richard Pzena 1,059,750 sh (+1.49%)
Robert Bruce 10,000 sh (unchged)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Pioneer Investments 22,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Mario Gabelli 104,070 sh (-2.86%)
Richard Snow 1,286,067 sh (-11.68%)
» More
Q3 2013

HSP Guru Trades in Q3 2013

Mario Gabelli 105,870 sh (+1.73%)
Michael Price 400,000 sh (unchged)
Pioneer Investments 22,000 sh (unchged)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Richard Pzena Sold Out
Steven Cohen Sold Out
John Rogers 4,436,305 sh (-7.79%)
Brian Rogers 2,500,000 sh (-9.09%)
Jeff Auxier 232,930 sh (-16.36%)
Larry Robbins 3,152,089 sh (-25%)
Richard Snow 811,590 sh (-36.89%)
» More
Q4 2013

HSP Guru Trades in Q4 2013

Jim Simons 39,500 sh (New)
Paul Tudor Jones 14,676 sh (New)
Steven Cohen 38,505 sh (New)
Mario Gabelli 117,670 sh (+11.15%)
John Rogers 4,670,630 sh (+5.28%)
Robert Bruce 10,000 sh (unchged)
Brian Rogers 2,500,000 sh (unchged)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Michael Price 400,000 sh (unchged)
Pioneer Investments Sold Out
Larry Robbins Sold Out
Richard Snow 804,722 sh (-0.85%)
Jeff Auxier 218,080 sh (-6.38%)
» More
Q1 2014

HSP Guru Trades in Q1 2014

Brian Rogers Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HSP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2013-03-31 Add 61.62%0.65%$28.96 - $35.99 $ 4333%400000
Vanguard Health Care Fund 2013-03-31 Add 242.15%0.62%$28.96 - $35.99 $ 4333%6826070
Meridian Funds 2013-03-31 New Buy0.28%$28.96 - $35.99 $ 4333%237400
Mario Gabelli 2013-03-31 Add 124.92%0.01%$28.96 - $35.99 $ 4333%107130
Mario Gabelli 2012-06-30 Add 60.16%$31.2 - $37.29 $ 4327%41530
Jean-Marie Eveillard 2012-03-31 Sold Out 0.09%$30.14 - $38.14 $ 4330%0
Ronald Muhlenkamp 2012-03-31 Sold Out 0.09%$30.14 - $38.14 $ 4330%0
Mario Gabelli 2012-03-31 Add 268.85%0.01%$30.14 - $38.14 $ 4330%25930
Ronald Muhlenkamp 2011-12-31 Reduce -91.31%1.4%$27.29 - $38.76 $ 4336%14650
Michael Price 2011-12-31 New Buy1.2%$27.29 - $38.76 $ 4336%237500
Meridian Funds 2011-12-31 Sold Out 0.23%$27.29 - $38.76 $ 4336%0
Vanguard Health Care Fund 2011-12-31 Add 91.32%0.16%$27.29 - $38.76 $ 4336%2095070
Jean-Marie Eveillard 2011-12-31 New Buy0.09%$27.29 - $38.76 $ 4336%650013
Mario Gabelli 2011-12-31 New Buy$27.29 - $38.76 $ 4336%7030
Ronald Muhlenkamp 2011-09-30 Reduce -36.56%0.93%$34.44 - $54.22 $ 43-6%168510
Meridian Funds 2011-09-30 Add 1019.87%0.21%$34.44 - $54.22 $ 43-6%169100
George Soros 2011-09-30 Sold Out 0.0798%$34.44 - $54.22 $ 43-6%0
George Soros 2011-06-30 Reduce -85.73%0.52%$53.74 - $58.13 $ 43-22%100200
Meridian Funds 2011-06-30 New Buy0.03%$53.74 - $58.13 $ 43-22%15100
George Soros 2011-03-31 Add 243.49%0.33%$51.05 - $56.8 $ 43-20%702103
Mario Gabelli 2011-03-31 Sold Out $51.05 - $56.8 $ 43-20%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira, Inc.

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Top Ranked Articles about Hospira, Inc.

John Rogers Comments on Hospira Inc.
Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible. Read more...
Brian Rogers' Top 3 Increases and Decreases of Q2
Brian Rogers of the T. Rowe Price Equity Income Fund recently released his second quarter portfolio updates which report that he has one new holding, 15 increases, 26 reductions and two stocks that he sold out of. Brian Rogers has been the portfolio manager of T. Rowe Price Equity Income Fund since its inception in 1985. Rogers looks for common stocks of established firms that are expected to pay above-average dividends. Read more...

Ratios

vs
industry
vs
history
P/B 2.40
HSP's P/B is ranked higher than
68% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. HSP: 2.40 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 2.4

1.52
5.83
P/S 1.78
HSP's P/S is ranked higher than
74% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. HSP: 1.78 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 2.89
Current: 1.78

0.99
2.89
EV-to-EBIT 500.00
HSP's EV-to-EBIT is ranked lower than
78% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. HSP: 500.00 )
HSP' s 10-Year EV-to-EBIT Range
Min: 10   Max: 508.2
Current: 500

10
508.2
Shiller P/E 35.60
HSP's Shiller P/E is ranked higher than
58% of the 363 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. HSP: 35.60 )
HSP' s 10-Year Shiller P/E Range
Min: 12.55   Max: 36.53
Current: 35.6

12.55
36.53

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.10
HSP's Price/Tangible Book is ranked higher than
56% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. HSP: 4.10 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 20.95
Current: 4.1

3.04
20.95
Price/DCF (Projected) 1.50
HSP's Price/DCF (Projected) is ranked higher than
76% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. HSP: 1.50 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 1.45
Current: 1.5

0.91
1.45
Price/Median PS Value 0.90
HSP's Price/Median PS Value is ranked higher than
80% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. HSP: 0.90 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.38
Current: 0.9

0.62
1.38
Earnings Yield (Greenblatt) 0.20
HSP's Earnings Yield (Greenblatt) is ranked lower than
69% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. HSP: 0.20 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 0.2

0.2
10
Forward Rate of Return (Yacktman) 3.60
HSP's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. HSP: 3.60 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.1   Max: 18.8
Current: 3.6

4.1
18.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany
Hospira, Inc. was incorporated in Delaware on September 16, 2003, as a wholly owned subsidiary of Abbott Laboratories. On April 30, 2004, it began operating as an independent company. The Company is a global provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company's specialty injectable pharmaceutical products category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solutions, nutritionals and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. It also offers infusion therapy solutions in its VisIV(TM) next-generation non-PVC, non-DEHP I.V. container, an I.V. bag with advanced safety and environmentally friendly features. Its contract manufacturing services are offered through its One2One(SM) services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to the company's pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that serve through its own sales force and its distributors. In the U.S., the

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide